KeyNeurotek AG to Start European Phase II Trial in Traumatic Brain Injury (TBI)
Traumatic brain injuries caused for example by accidents at work or at home, result in complex and often life threatening injuries of the brain, which at present cannot be treated pharmacologically. The drug candidate KN 38-7276 has been exclusively inlicensed by KeyNeurotek from Bayer Healthcare AG (Leverkusen, Germany) in 2005. KN 38-7271 is a novel cannabinoid receptor agonist activating both CB1 and CB2 cannabinoid receptors, thereby working via a dual mechanism of action: It has a lasting positive effect on the natural protection mechanisms of the very sensitive nerve cells and it also prevents the excessive inflammatory reactions common in brain injury.
Results of the Phase II study are expected in the first half of 2008.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.